Silo Pharma Announces filing Of Patent For Treatment Of Fibromyalgia; Action Supports Planned IND Package Submission To FDA For SP-26
SPU-26 Pain Management Using Ketamine Composition
Action supports planned IND package submission to FDA for SP-26
ENGLEWOOD CLIFFS, NJ, March 27, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) (the
Immunoprecise Antibodies Ltd. The Parent Company Of BioKey Announces European Patent Office To Grant Patent Application For Foundational HYFT Technology
Company Received Official Notice from the European Patent Office (EPO) for the Decision to Grant its Patent Application on April 5th, 2023. The Patent was Initially Filed February 7th, 2020.
Patent Application Covers
FDA Approves Pharming’s Immune Disorder Drug, As First APDS Therapy
The FDA approved Pharming Group N.V.’s (NASDAQ:PHAR) Joenja (leniolisib) for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric…
Pharming Announces U.S. FDA Approval Of Joenja As The First And Only Treatment Indicated For APDS; Expected To Launch In The U.S. In Early April
APDS (activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome) is a rare and progressive primary immunodeficiency
Joenja® is a targeted treatment of APDS for adult and pediatric patients 12 years of age and
Second Setback For Incyte’s LIMBER Program – Analyst Says ‘Resolution Timelines Unclear To Assess Impact’
The FDA issued a complete response letter (CRL) to Incyte Corporation (NASDAQ:INCY) ruxolitinib extended-release (XR) tablets, a JAK1/JAK2 inhibitor, for once-daily (QD)…
Second Setback For Incyte’s LIMBER Program – Analyst Says ‘Resolution Timelines Unclear To Assess Impact’
The FDA issued a complete response letter (CRL) to Incyte Corporation (NASDAQ:INCY) ruxolitinib extended-release (XR) tablets, a JAK1/JAK2 inhibitor, for once-daily (QD)…
Cidara’s Lower Than Expected Q4 Earnings Overshadows FDA Nod For Antifungal Treatment
The FDA approved Cidara Therapeutics Inc’s (NASDAQ:CDTX) antifungal Rezzayo (rezafungin) under priority review for treating candidemia and invasive candidiasis in adults…
Evoke Pharma & EVERSANA Announce Compelling Real-World Data On The Impact Of GIMOTI In Reducing The Utilization Of Healthcare Resources To Be Presented At The Academy Of Managed Care Pharmacy 2023
Evoke Pharma, Inc. (NASDAQ:EVOK),a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, and